SGMO – sangamo therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain [Yahoo! Finance]
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Form EFFECT SANGAMO THERAPEUTICS,
Form S-8 SANGAMO THERAPEUTICS,
Form S-3 SANGAMO THERAPEUTICS,
Form SC 13G/A SANGAMO THERAPEUTICS, Filed by: VANGUARD GROUP INC
Form 10-Q SANGAMO THERAPEUTICS, For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.